Administration of recombinant interleukin-2 reduces the local parasite load of patients with disseminated cutaneous leishmaniasis

J Infect Dis. 1990 Apr;161(4):775-80. doi: 10.1093/infdis/161.4.775.

Abstract

Three patients with disseminated cutaneous leishmaniasis received three intranodular injections of 10 micrograms of recombinant interleukin 2 (rIL-2) at 48-h intervals. After 7 and 14 days, 4-mm punch biopsies were taken of control and injected nodules and processed for histology, electron microscopy, immunocytochemistry, and parasite culture. Control sites exhibited loose infiltrates of parasitized macrophages and T cells predominantly of the CD8+ phenotype. Amastigotes were present in large numbers and were found distributed within tightly apposed endosomes and larger vacuoles. After the administration of rIL-2, there was a prominent influx of T cells, predominantly of the CD4+ phenotype, and an increased number of plasma cells. At 7 days, leishmanial amastigotes were present in either the same or somewhat reduced numbers but predominantly within large, lucent vacuoles. By 14 days the number of amastigotes was strikingly lower. Lymphokine-treated skin sites became sterile in two patients, as evaluated by parasite culture after rIL-2 injection. The results suggest that the local administration of rIL-2 induces a beneficial enhancement of the cellular immunity with a consequent disposal of parasites in the cutaneous site.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adolescent
  • Animals
  • Humans
  • Immunity, Cellular
  • Interleukin-2 / therapeutic use*
  • Leishmania / immunology
  • Leishmania / ultrastructure
  • Leishmaniasis / therapy*
  • Macrophages / parasitology
  • Macrophages / ultrastructure
  • Male
  • Microscopy, Electron
  • Middle Aged
  • Recombinant Proteins / therapeutic use
  • Skin / parasitology

Substances

  • Interleukin-2
  • Recombinant Proteins